TY - JOUR
T1 - Clinical and epidemiological features of Chryseobacterium indologenes infections
T2 - Analysisof 215 cases
AU - Chen, Fu Lun
AU - Wang, Giueng Chueng
AU - Teng, Sing On
AU - Ou, Tsong Yih
AU - Yu, Fang Lan
AU - Lee, Wen Sen
N1 - Funding Information:
The authors thank Chi-Won Suk for reviewing the chest radiographs and Tzu-Ting Chen for microbiolotechnological support. We thank Professor Winston W. Shen for constructive editing comments in a previous version of this manuscript. We also acknowledge the financial support from the Center of Excellence for Clinical Trial and Research in Neuroscience, Wan Fang Hospital, Taipei Medical University, Taiwan.
PY - 2013/12
Y1 - 2013/12
N2 - Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.
AB - Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.
KW - Chryseobacterium indologenes
KW - Colistin
KW - Tigecycline
KW - Trimethoprim-sulfamethoxazole
UR - http://www.scopus.com/inward/record.url?scp=84889663753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889663753&partnerID=8YFLogxK
U2 - 10.1016/j.jmii.2012.08.007
DO - 10.1016/j.jmii.2012.08.007
M3 - Article
C2 - 23022462
AN - SCOPUS:84889663753
SN - 1684-1182
VL - 46
SP - 425
EP - 432
JO - Journal of Microbiology, Immunology and Infection
JF - Journal of Microbiology, Immunology and Infection
IS - 6
ER -